SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
2020 · Journal of Thoracic Oncology · 476 citations
https://doi.org/10.1016/j.jtho.2020.09.009
A
Achim A. Jungbluth
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
552
Papers
35.5K
Citations
97
h-index
264
i10-index
Achim A. Jungbluth is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Immunotherapy and Immune Responses & Monoclonal and Polyclonal Antibodies Research & Cancer Immunotherapy and Biomarkers. The author has an h-index of 97, co-authored 470 publications.
ORCID: 0000-0002-8949-2333Papers by this author
worksDNA methylation-based classification of sinonasal undifferentiated carcinoma
2019 · Modern Pathology · 133 citations
https://doi.org/10.1038/s41379-019-0285-x
Cancer–testis antigen expression in triple-negative breast cancer
2010 · Annals of Oncology · 98 citations
https://doi.org/10.1093/annonc/mdq325
Anatomic position determines oncogenic specificity in melanoma
2022 · Nature · 93 citations
https://doi.org/10.1038/s41586-022-04584-6
A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
2003 · British Journal of Cancer · 38 citations
https://doi.org/10.1038/sj.bjc.6600751
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
2018 · Theranostics · 38 citations
https://doi.org/10.7150/thno.26585
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat